RT Journal Article
SR Electronic
T1 Rapid and accurate point-of-care testing for SARS-CoV2 antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.30.20241208
DO 10.1101/2020.11.30.20241208
A1 Esmail, Sally
A1 Knauer, Michael J.
A1 Abdoh, Husam
A1 Chin-Yee, Benjamin
A1 Stogios, Peter
A1 Seitova, Almagul
A1 Hutchinson, Ashley
A1 Yusifov, Farhad
A1 Skarina, Tatiana
A1 Evdokimova, Elena
A1 Ackloo, Suzanne
A1 Lowes, Lori
A1 Voss, Courtney
A1 Hedley, Benjamin D.
A1 Bhayana, Vipin
A1 Chin-Yee, Ian
A1 Li, Shawn S-C.
YR 2020
UL http://medrxiv.org/content/early/2020/12/02/2020.11.30.20241208.abstract
AB The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has grown into worst public health crisis since the 1918 influenza pandemic. As COVID-19 continues to spread around the world, there is urgent need for a rapid, yet accurate antibody test to identify infected individuals in populations to inform health decisions. We have developed a rapid, accurate and cost-effective serologic test based on antibody-dependent agglutination of antigen-coated latex particles, which uses ∼5 µl plasma and takes <5 min to complete with no instrument required. The simplicity of this test makes it ideal for point-of-care (POC) use at the community level. When validated using plasma samples that are positive or negative for SARS-CoV-2, the agglutination assay detected antibodies against the receptor-binding domain of the spike (S-RBD) or the nucleocapsid (N) protein of SARS-CoV-2 with 100% specificity and ∼98% sensitivity. Furthermore, we found that the strength of the S-RBD antibody response measured by the agglutination assay correlated with the efficiency of the plasma in blocking RBD binding to the angiotensin converting enzyme 2 (ACE2) in a surrogate neutralization assay, suggesting that the agglutination assay may be used to identify individuals with virus-neutralizing antibodies. Intriguingly, we found that >92% of patients had detectable antibodies on the day of positive viral RNA test, suggesting that seroconversion may occur earlier than previously thought and that the agglutination antibody test may complement RNA testing for POC diagnosis of SARS-CoV-2 infection.Competing Interest StatementSE, CV and SSCL are inventors in a provisional patent submitted by Western UniversityFunding StatementThis work was supported by a grant (to SSCL, ICY, MK, BCY and VB) from the Ontario Research Fund-COVID-19 Rapid Research Fund and by the Toronto COVID-19 Action Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood samples were collected following a protocol (study number: 116284) approved by the Research Ethics Board (REB) of Western University. The plasma samples were de-identified prior to transfer from the Laboratory of Clinical Medicine (London Health Sciences Center, London, Canada) to a biosafety Level 3 (CL3) lab (ImPaKT, Western University) following Transportation of Dangerous Goods (TDG) guidelines. All plasma samples were heat-inactivated at 56 oC for 30 minutes at the ImPaKT CL3 facility as per Western university biosafety regulation. Heat inactivated plasma samples were then transferred to the testing laboratory.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon request